Gross Profit Comparison: Vertex Pharmaceuticals Incorporated and Pharming Group N.V. Trends

Vertex vs. Pharming: A Decade of Financial Growth

__timestampPharming Group N.V.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201421595165519428000
Thursday, January 1, 20156590427906794000
Friday, January 1, 2016117685421491717000
Sunday, January 1, 2017925870382213533000
Monday, January 1, 20181292038432638058000
Tuesday, January 1, 20191654124473615063000
Wednesday, January 1, 20202030564305469383000
Friday, January 1, 20211696700716670200000
Saturday, January 1, 20221880600007850400000
Sunday, January 1, 20232201040008607000000
Monday, January 1, 20249489600000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Growth: Vertex Pharmaceuticals vs. Pharming Group

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their success and innovation. Over the past decade, Vertex Pharmaceuticals Incorporated has demonstrated a remarkable growth trajectory in gross profit, surging from approximately $519 million in 2014 to an impressive $8.6 billion in 2023. This represents a staggering increase of over 1,500%, underscoring Vertex's dominance in the biotech sector.

Conversely, Pharming Group N.V. has shown a more modest growth, with gross profits rising from around $21 million in 2014 to $220 million in 2023. While this is a significant tenfold increase, it highlights the competitive gap between the two companies.

This comparison not only reflects the dynamic nature of the pharmaceutical industry but also emphasizes the importance of strategic innovation and market positioning in achieving financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025